An open-label trial of granulocyte macrophage colony stimulating factor therapy for moderate symptomatic pulmonary alveolar proteinosis

Chest

Volumn 130, Issue 1, 2006, Pages 227-237

  Venkateshiah, Saiprakash B ^a,b   Yan, Tom D ^a   Bonfield, Tracey L ^a   Thomassen, Mary Jane ^a   Meziane, Moulay ^a   Czich, Carmen ^a   Kavuru, Mani S ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b CREIGHTON UNIVERSITY   (United States)

Author keywords

Antibodies; Granulocyte macrophage colony stimulating factor; Immunotherapy; Pulmonary alveolar proteinosis

Indexed keywords

ANTIBODY; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR ANTIBODY; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; UNCLASSIFIED DRUG;

ADULT; ARTHRALGIA; ARTICLE; BONE MARROW TOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; ERYTHEMA; FEMALE; HUMAN; IMMUNOTHERAPY; INJECTION SITE EDEMA; LUNG ALVEOLUS PROTEINOSIS; LUNG DIFFUSION CAPACITY; LUNG TOXICITY; MALAISE; MALE; OPEN STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; SHORT FORM 36; TOTAL LUNG CAPACITY;

EID: 33746371698     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.130.1.227     Document Type: Article

References (23)

1. Seymour JF, Presneill JJ. Pulmonary alveolar proteinosis: progress in the first 44 years. Am J Respir Crit Care Med 2002; 166:215-235
2. Morgan C. The benefits of whole lung lavage in pulmonary alveolar proteinosis. Eur Respir J 2004; 23:503-505
3. Cooke KR, Nishinakamura R, Martin TR, et al. Persistence of pulmonary pathology and abnormal lung function in IL-3/GM-CSF/IL-5 β c receptor-deficient mice despite correction of alveolar proteinosis after BMT. Bone Marrow Transplant 1997; 20:657-662
4. Dranoff G, Crawford AD, Sadelain M, et al. Involvement of granulocyte-macrophage colony-stimulating factor in pulmonary homeostasis. Science 1994; 264:713-716
5. Huffman JA, Hull WM, Dranoff G, et al. Pulmonary epithelial cell expression of GM-CSF corrects the alveolar proteinosis in GM-CSF-deficient mice. J Clin Invest 1996; 97:649-655
6. Nishinakamura R, Wiler R, Dirksen U, et al. The pulmonary alveolar proteinosis in granulocyte macrophage colony-stimulating factor/interleukins 3/5 beta c receptor-deficient mice is reversed by bone marrow transplantation. J Exp Med 1996; 183:2657-2662
7. Stanley E, Lieschke GJ, Grail D, et al. Granulocyte/macrophage colony-stimulating factor-deficient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pathology. Proc Natl Acad Sci U S A 1994; 91:5592-5596
8. Thomassen MJ, Yi T, Raychaudhuri B, et al. Pulmonary alveolar proteinosis is a disease of decreased availability of GM-CSF rather than an intrinsic cellular defect. Clin Immunol 2000; 95:85-92
9. Kitamura T, Tanaka N, Watanabe J, et al. Idiopathic pulmonary alveolar proteinosis as an autoimmune disease with neutralizing antibody against granulocyte/macrophage colony-stimulating factor. J Exp Med 1999; 190:875-880
10. Seymour JF, Dunn AR, Vincent JM, et al. Efficacy of granulocyte- macrophage colony-stimulating factor in acquired alveolar proteinosis. N Engl J Med 1996; 335:1924-1925
11. Kavuru MS, Sullivan EJ, Piccin R, et al. Exogenous granulocyte-macrophage colony-stimulating factor administration for pulmonary alveolar proteinosis. Am J Respir Crit Care Med 2000; 161:1143-1148
12. Seymour JF, Presneill JJ, Schoch OD, et al. Therapeutic efficacy of granulocyte-macrophage colony-stimulating factor in patients with idiopathic acquired alveolar proteinosis. Am J Respir Crit Care Med 2001; 163:524-531
13. Barraclough RM, Gillies AJ. Pulmonary alveolar proteinosis: a complete response to GM-CSF therapy. Thorax 2001; 56:664-665
14. Schoch OD, Schanz U, Koller M, et al. BAL findings in a patient with pulmonary alveolar proteinosis successfully treated with GM-CSF. Thorax 2002; 57:277-280
15. Bonfield TL, Kavuru MS, Thomassen MJ. Anti-GM-CSF titer predicts response to GM-CSF therapy in pulmonary alveolar proteinosis. Clin Immunol 2002; 105:342-350
16. Bonfield TL, Russell D, Burgess S, et al. Autoantibodies against granulocyte macrophage colony-stimulating factor are diagnostic for pulmonary alveolar proteinosis. Am J Respir Cell Mol Biol 2002; 27:481-486
17. Remy-Jardin M, Giraud F, Remy J, et al. Importance of ground-glass attenuation in chronic diffuse infiltrative lung disease: pathologic-CT correlation. Radiology 1993; 189:693-698
18. Bonfield TL, Raychaudhuri B, Malur A, et al. PU.1 regulation of human alveolar macrophage differentiation requires granulocyte-macrophage colony-stimulating factor. Am J Physiol Lung Cell Mol Physiol 2003; 285:L1132-L1136
19. Shibata Y, Berclaz PY, Chroncos ZC, et al. GM-CSF regulates alveolar macrophage differentiation and innate immunity in the lung through PU.1. Immunity 2001; 15:557-567
20. Tazawa R, Hamano E, Arai T, et al. Granulocyte-macrophage colony-stimulating factor and lung immunity in pulmonary alveolar proteinosis. Am J Respir Crit Care Med 2005; 171:1142-1149
21. Reed JA, Ikegami M, Cianciolo ER, et al. Aerosolized GM-CSF ameliorates pulmonary alveolar proteinosis in GM-CSF-deficient mice. Am J Physiol 1999; 276:L556-L563
22. Seymour JF, Begley CG, Dirksen U, et al. Attenuated hematopoietic response to granulocyte-macrophage colony-stimulating factor in patients with acquired pulmonary alveolar proteinosis. Blood 1998; 92:2657-2667
23. Seymour JF, Doyle IR, Nakata K, et al. Relationship of anti-GM-CSF antibody concentration, surfactant protein A and B levels, and serum LDH to pulmonary parameters and response to GM-CSF therapy in patients with idiopathic alveolar proteinosis. Thorax 2003; 58:252-257